Girding For New GERD Therapies
Executive Summary
Two biotech companies, Addex Pharmaceuticals and XenoPort, are in a tight race to develop successors to the generic or soon-to-be-generic blockbuster proton pump inhibitors. As the firms' drugs proceed through clinical trials, their respective outcomes are an object lesson for biotechs and pharmaceutical companies looking to enter a crowded space already well served by existing medicines.
You may also be interested in...
XenoPort Gives Up On Reflux Drug After It Fails To Beat Placebo
Negative results thwart a potential partnership strategy surrounding arbaclofen placerbil, which still holds potential in spasticity.
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
The discovery of metabotropic glutamate receptors in the early '90s opened up a new world of potential drug targets in CNS diseases and beyond. But targeting specific mGluRs proved difficult; eventually the challenge of designing selective molecules led to breakthroughs modulating receptors at sites distinct from the endogenous binding site. This so-called allosteric modulation may help to clear a logjam of undruggable GPCRs and other receptors. Creating drug-like molecules remains a challenge but industry, after some false starts, is poised to make advances as compounds begin to hit proof-of-concept in man.
Adventures in Glutamate: The Difficult and Expensive Path of Novelty in Drug Discovery
The discovery of metabotropic glutamate receptors in the early '90s opened up a new world of potential drug targets in CNS diseases and beyond. But targeting specific mGluRs proved difficult; eventually the challenge of designing selective molecules led to breakthroughs modulating receptors at sites distinct from the endogenous binding site. This so-called allosteric modulation may help to clear a logjam of undruggable GPCRs and other receptors. Creating drug-like molecules remains a challenge but industry, after some false starts, is poised to make advances as compounds begin to hit proof-of-concept in man.